Logo
Kairax™ Fine (1x1ml)

Kairax™ Fine (1x1ml)

Kairax

Dermal filler
  • CE Certified hyaluronic acid dermal filler (Class III medical device) for use by trained healthcare professionals.
  • Part of the Kairax range (Fine, Deep, Sub Q), all promoted as fully CE approved and containing lidocaine.
  • Manufactured under medical device quality systems consistent with international standards for sterile injectable implants.
  • Supported by official Kairax brochure describing composition (cross Linked HA 24 mg/ml, lidocaine 0.3%), manufacturing technology and safety testing.
Low-viscosity hyaluronic acid dermal filler for fine lines and delicate areas

Description

Kairax™ Fine (1x1ml) is a low-viscosity, CE-marked hyaluronic acid dermal filler with lidocaine, specifically formulated for the treatment of fine lines and delicate facial areas. Containing 24 mg/ml of cross-linked hyaluronic acid and 0.3% numbing agent (lidocaine), it provides subtle, natural-looking volume while blending seamlessly with the surrounding tissue. Kairax Fine has the lowest viscoelasticity in the Kairax range (Fine, Deep, Sub-Q) and is ideal for soft corrections in areas such as crow’s feet, periorbital lines and lip lines, as well as for gentle lip contour enhancement. The smooth monophasic gel allows precise placement, minimal swelling and bruising, and comfortable treatment with predictable, refined results.

Bnefits

  • Low-viscosity hyaluronic acid gel optimised for fine lines and delicate facial areas.
  • Formulated with 24 mg/ml cross-linked HA for effective yet subtle volumising and hydration.
  • Contains 0.3% lidocaine to enhance patient comfort during injection.
  • Smooths fine lines such as crow’s feet, periorbital lines and lip lines.
  • Restores natural-looking volume without overfilling, ensuring soft, seamless integration with facial contours.
  • High-quality, non-animal derived hyaluronic acid that is 100% biodegradable and naturally present in the human body.
  • Designed to minimise swelling and bruising thanks to optimised gel structure and purified raw materials.
  • Monophasic, CE-certified gel with undetected BDDE levels in many specifications, supporting a high safety profile.
  • Results are noticeable after a single treatment, with optimal effects typically seen within 2–4 weeks.
  • Part of a full professional range (Fine, Deep, Sub-Q) enabling tailored treatment according to wrinkle depth and desired volume.

Indications

  • Correction of superficial and fine lines in delicate areas.
  • Crow’s feet around the lateral canthus (eye area).
  • Periorbital fine lines.
  • Perioral and lip lines (smoker’s lines).
  • Subtle lip border and contour definition.
  • Light volumising and refinement of delicate facial contours where a soft, natural result is desired.
  • General rejuvenation of fine, etched lines in thin-skinned areas of the face.

Composition

  • Cross-linked hyaluronic acid 24 mg/ml (non-animal origin).
  • Lidocaine hydrochloride 0.3% as local anaesthetic.
  • Physiological buffer solution (phosphate-buffered, pH close to physiologic).
  • BDDE (1,4-butanediol diglycidyl ether) used as cross-linking agent; residual BDDE reported as undetected in technical specifications for the Kairax line.
  • Sterile excipients suitable for injectable hyaluronic acid dermal fillers.

Formulation

  • Monophasic, low-viscosity, cross-linked hyaluronic acid gel with lidocaine.
  • Lowest viscoelasticity within the Kairax range, tailored for superficial and fine-line correction.
  • Hydrophilic HA capable of binding significant amounts of water to improve hydration and skin turgor.
  • Biocompatible, biodegradable HA matrix designed to integrate smoothly into the superficial to mid-dermis.
  • Sterile, pyrogen-free, isotonic formulation in a ready-to-use prefilled syringe.

Packaging

  • 1 x 1 ml prefilled glass syringe of Kairax™ Fine with lidocaine.
  • Typically supplied with 2 x 30G needles (as listed by multiple distributors) suitable for fine-line injection.
  • Box labelled with product name, HA concentration (24 mg/ml), lidocaine content (0.3%), lot number, expiry date and CE mark.
  • Includes instructions for use (IFU) detailing indications, injection depth, precautions and storage.
  • Traceability labels provided for patient notes and clinic records.

Usage

  • For professional use only; must be administered by appropriately trained medical professionals experienced in dermal filler injections and facial anatomy.
  • Before use, inspect the blister and syringe; do not use if packaging is damaged or the product is past its expiry date.
  • Cleanse and disinfect the treatment area thoroughly and maintain strict aseptic technique throughout the procedure.
  • Attach the supplied 30G needle using the Luer-lock system and prime the syringe by expelling a small amount of gel to remove air.
  • Recommended injection depth for Kairax Fine is superficial to mid-dermis, depending on the area treated and desired effect.
  • Use small aliquots and appropriate techniques such as linear/threading, serial puncture or micro-bolus injections along fine lines and in delicate areas (e.g. periorbital, perioral, lip border).
  • Inject slowly with minimal pressure and consider aspiration where appropriate to reduce the risk of intravascular injection.
  • After injection, gentle moulding may be performed if necessary to ensure even distribution and a smooth contour; avoid excessive pressure, especially in delicate areas.
  • Advise patients to avoid make-up for several hours post-treatment (according to clinic protocol), and to avoid extreme temperatures, vigorous exercise, alcohol and manipulation of the treated area for 24 hours.
  • Follow the full instructions and safety recommendations outlined in the official Kairax brochure and IFU, and comply with local clinical guidelines and insurer requirements.

Contraindications

  • Hypersensitivity or known allergy to hyaluronic acid, lidocaine, amide-type local anaesthetics or any component of the product.
  • History of severe allergic reactions or anaphylaxis unless a careful risk–benefit assessment has been undertaken.
  • Presence of active skin infection, inflammation or disease at or near the intended injection site (e.g. herpes, acne, dermatitis, cellulitis).
  • Autoimmune disease, immunosuppression or uncontrolled systemic illness without specialist evaluation and explicit approval.
  • Bleeding disorders or concurrent anticoagulant/antiplatelet therapy that significantly increases bleeding risk, unless managed appropriately.
  • Pregnancy or breastfeeding, as safety has not been established in these populations.
  • Patients under 18 years of age.
  • Injection into blood vessels, intramuscularly, or into areas with permanent fillers, foreign bodies or poorly vascularised scar tissue without careful assessment.
  • Known porphyria, significant cardiac conduction disturbances or other conditions in which lidocaine use is contraindicated.
  • Any additional contraindications or warnings listed in the official Kairax instructions for use.

Adverse Effects

  • Common transient injection-site reactions such as redness, swelling, tenderness, pain, itching, bruising and small haematomas, typically resolving within a few days.
  • Temporary lumps, nodules, induration or firmness at the injection site, usually improving over time and with gentle massage if advised.
  • Asymmetry, undercorrection or overcorrection that may require adjustment or additional treatment.
  • Rare delayed inflammatory reactions or granulomatous responses, as with other hyaluronic acid fillers, which may require medical management.
  • Infection at the injection site if aseptic technique is not properly observed.
  • Very rare but serious complications from inadvertent intravascular injection, including vascular occlusion, tissue ischaemia, necrosis and, in high-risk facial areas, visual compromise or blindness.
  • Systemic lidocaine-related effects (e.g. CNS or cardiovascular symptoms) are theoretically possible if maximum safe doses are exceeded or if injected intravascularly, though unlikely at normal aesthetic doses.

Storage Conditions

  • Store at 2–25°C in a clean, dry place.
  • Do not freeze.
  • Keep the syringe in its original blister and outer carton to protect from light and physical damage until use.
  • Do not use after the expiry date printed on the packaging.
  • Single-use sterile device – do not resterilise and do not reuse any remaining product, syringe or needle.
  • Dispose of used needles and syringes in approved sharps containers according to local regulations.

Duration

Results are typically visible immediately after injection, with optimal refinement within 2\u20134 weeks. Clinical and distributor information for Kairax fillers generally indicates durability in the range of approximately 6\u20139 months in fine-line indications, depending on area, technique, product volume and individual patient metabolism.

Onset

Immediate improvement in fine lines and subtle volume upon injection, with further refinement as any initial redness or swelling subsides over the following days; best aesthetic integration usually observed within 2\u20134 weeks.

Browse more Dermal filler

Top Treatments

Top Cities in the UK